The mechanisms that cause tumors such as melanomas to metastasize into peripheral lymphatic capillaries are poorly defined. Non-mutually-exclusive mechanisms are lymphatic endothelial cell (LEC) chemotaxis and proliferation in response to tumor cells (chemotaxis-lymphangiogenesis hypothesis) or LECs may secrete chemotactic agents that attract cancer cells (chemotactic metastasis hypothesis). Using migration assays, we found evidence supporting both hypotheses. Conditioned medium (CM) from metastatic malignant melanoma (MMM) cell lines attracted LEC migration, consistent with the lymphangiogenesis hypothesis. Conversely, CM from mixed endothelial cells or LECs, but not blood endothelial cells, attracted MMM cells but not non-metastatic melanoma cells, consistent with the chemotactic metastasis hypothesis. MMM cell lines expressed CCR7 receptors for the lymphatic chemokine CCL21 and CCL21 neutralizing antibodies prevented MMM chemotaxis in vitro. To test for chemotactic metastasis in vivo tumor cells were xenotransplanted into nude mice B1 cm from an injected LEC depot. Two different MMM grew directionally towards the LECs, whereas non-metastatic melanomas did not. These observations support the hypothesis that MMM cells grow towards regions of high LEC density owing to chemotactic LEC secretions, including CCL21. This chemotactic metastasis may contribute to the close association between metastasizing tumor cells and peritumor lymphatic density and promote lymphatic invasion.
Introduction
Malignant melanoma, the most lethal skin cancer, accounts for 75% of all skin cancer mortality. Death is due to metastases, and the initial site of metastasis is most commonly the regional lymph nodes. Once regional nodal metastases are clinically obvious, 70-85% of patients have distant occult metastases (Wagner et al., 2000) and the 10 year survival rate falls to 35% (White et al., 2002) . The route for metastasis to the regional nodes is through the local lymphatic system rather than bloodstream (Elias et al., 1977) . In animal models, tumors that stimulate lymphangiogenesis (the formation of lymphatic capillaries from pre-existing lymphatic capillaries), by secreting bioactive agents, notably vascular endothelial growth factor C (VEGF-C) (Skobe et al., 2001) , have a greater incidence of metastasis than non-lymphangiogenic tumors. Similarly, human cancers that metastasize through the lymphatic system have a raised lymphatic vessel density around the tumor compared with control tissue or non-metastatic tumors (Dadras et al., 2003; Shields et al., 2004) . These findings in humans and animals have led to a lymphangiogenesis hypothesis of metastasis, namely certain tumors secrete lymphangiogenic agents (e.g. VEGF-C), which raises the density of microlymphatics at the tumor margins and thus raises the probability of tumor cells invading the lymphatic capillary lumen.
In addition, a second, less studied mechanism may contribute to tumor metastasis into lymphatics. The lymphatic endothelial cells (LECs) might themselves release chemotactic agents that direct tumors with an appropriate expression of chemotactic receptors to grow and migrate towards pre-existing lymphatic capillaries. Several proteins secreted by LECs have been identified recently, including the chemokine ligands CCL21 and CCL19 (Kriehuber et al., 2001; Luther et al., 2002; Takeuchi et al., 2004) , which have been shown to be involved in T cell and dendritic cell trafficking to lymph nodes.
The chemotactic metastasis hypothesis will be particularly important if there is a heterogeneous distribution of lymphatic density (LD, number per unit tissue area). Quantitative measurements show that lymphatic capillary density in many tissues, including the dermis, is uneven over a space scale of millimeters (Stanton et al., 1997; Shields et al., 2004) , and can differ several fold between different sites in the same tissue (Stanton et al., 1999) . Thus, if lymphatic endothelium produces chemotactic factors to which a particular tumor possesses receptors, that tumor can be expected to spread preferentially in the direction of the highest LD, resulting in association between high peri-tumor LD and lymphatic metastasis.
We have investigated the 'chemotactic metastasis' hypothesis experimentally, both in vitro and in vivo. We found evidence that LECs migrate towards metastatic melanoma culture medium in vitro, consistent with the lymphangiogenesis hypothesis. We also found that malignant melanoma cells migrate towards culture medium from LECs in vitro; that malignant melanoma in vivo shows directed growth towards LECs in a mouse model; and that the stochastic variation in normal dermal LD encompasses the high density observed around metastasizing malignant melanoma. This set of observations supports the 'chemotactic metastasis' hypothesis.
Results

Melanoma cells secrete factors that stimulate lymphatic endothelial cell migration
To determine whether LECs could migrate towards melanoma cells, conditioned medium (CM) from a malignant melanoma cell line, A375, was placed in the bottom of a Boyden chamber, and LECs seeded in the top. Melanoma cell CM caused a 1974.4-fold increase in LEC migration compared with control (n ¼ 3, Po0.001, Bonferroni test; Figure 1a ). The LEC migration induced by melanoma CM was significantly attenuated by the VEGFR-3 inhibitor MAZ51 (5 mM, 4.071.0-fold, n ¼ 3, Po0.001 compared with A375CM, Bonferroni test). VEGF-C itself also stimulated migration of LECs by 1472.0-fold (n ¼ 3, Po0.001, Bonferroni test), and this was completely abolished by treatment with 5 mM MAZ51. VEGF-A did not significantly stimulate the migration of LECs (1.970.3-fold, n ¼ 12, P>0.05, Bonferroni test). In contrast, A375 melanoma cell CM did not significantly increase the migration of blood vascular endothelial cells (BECs) (1.570.3-fold, n ¼ 3, P>0.05, Bonferroni test; Figure 1b ). VEGF-C likewise had no significant effect on the migration of BECs (1.670.19-fold, n ¼ 3, P>0.05, Bonferroni test). By contrast, VEGF-A stimulated BEC migration by 3.970.09-fold (n ¼ 3, Po0.001, Bonferroni test), which was inhibited by a VEGF-A neutralizing antibody (1.870.23-fold, n ¼ 3, Po0.01 compared with VEGF-A, Bonferroni test), but not by 5 mM MAZ51 (3.670.6-fold, n ¼ 3).
To determine whether A375 cells secrete VEGF-C, an ELISA was carried out on the CM. CM from A375 cells contained 1.570.4 ng/ml VEGF-C, whereas a nonmelanoma cell line (Chinese hamster ovary cells) secreted only 163724 pg/ml, which was close to the detection limit for VEGF-C (110 pg/ml) and significantly lower than A375 cells (n ¼ 3, Po0.05, unpaired t-test).
These results showed that the migratory response of cultured LECs to melanoma CM and VEGF-C is specific to the lymphatic endothelium phenotype (podoplanin-positive endothelium) and is not a general property of all endothelial cells. The results in Figure 1 thus complement the lymphangiogenesis hypothesis.
Lymphatic endothelial cells secrete soluble factors that stimulate melanoma cell migration To determine whether endothelial cells (and specifically LECs) release soluble factors that can attract melanoma cells, their migration to endothelial CM was measured. In an initial study, the CM from heterogeneous human dermal endothelial cells (HDECs, a mixture of LECs and BECs) stimulated melanoma cell migration very powerfully, by 2475 times control (Figure 2a , n ¼ 6, Po0.001, Bonferroni test). This was significantly reduced (to 6.970.56 times control) by a neutralizing antibody against the lymphatic secreted chemokine CCL21 (n ¼ 3, Po0.01, compared with non-specific IgG, Bonferroni test). Addition of the VEGF receptor-3 blocker MAZ51 to the CCL21 neutralizing antibody caused no further inhibition of migration (Figure 2a ). Control studies showed that CM from CHO cell culture did not stimulate melanoma cell migration (0.970.1 times control, n ¼ 3; Figure 2a ). The initial set of experiments thus demonstrated chemotaxis of malignant melanoma cells towards a product of endothelial cells, and implicated a product specifically of LECs. This led to further experiments with isolated LECs.
To test whether LECs contributed to the above chemotactic response, CM from LECs (i.e. podoplaninpositive endothelium isolated from the parent HDECs) was applied to the chamber (Figure 2b ). LEC-CM significantly stimulated the transmigration of the malignant melanoma cell line A375, by 9.070.35 times control (n ¼ 3, Po0.001, Bonferroni test). This was significantly greater migration than that induced by the conditioned media of the parent HDECs before isolation (5.270.47 times control, Po0.001, SNK, n ¼ 3). In contrast, the CM from the BECs purified from the parent HDECs did not stimulate migration of the melanoma cells (1.170.18 times control, Po0.001 compared with HDECs and LECs (Figure 2b) ).
The stimulatory effect of LEC-CM on cancer cell migration was abolished by the neutralizing antibody to CCL21 (Figure 2b ), indicating that this lymphaticgenerated chemokine had a key role in driving the cancer cell migration. The CCL21 neutralizing antibody had no effect on BEC-CM induced migration (1.770.17-fold).
To test directly whether A375 melanoma cell migration can be induced by CCL21, this was added to the lower half of a Boyden chamber, again with the A375 cells in the upper half. CCL21 caused a significant increase in metastatic melanoma cell migration (2.470.5 times control, n ¼ 3, Po0.05; Figure 2c ), which was completely blocked by the addition of neutralizing antibody to CCL21 (test/control migration 0.5370.21, Po0.05 compared with CCL21 alone, n ¼ 3). To test whether VEGF-C too contributed to the migratory response to LEC-CM, VEGF-C was added to the CCL21 medium. The combination caused no extra migration, the test/ control ratio being 2.270.55 (Po0.05 compared with control; P>0.1 compared with CCL21 alone). Correspondingly, addition of the VEGF-C receptor blocker MAZ51 to the neutralizing antibody caused no extra suppression of the migratory response to VEGF-C plus CCL21 (test/control ratio 0.6870.19, P ¼ 0.05 compared with response to VEGF-C plus CCL-21, n ¼ 3). A CCL21 ELISA was performed and showed that whereas CCL21 was detected in the parent HDEC-CM (2267185 pg/ml, n ¼ 6) and LEC-CM isolated from those HDECs (6827198 pg/ml, n ¼ 3), CCL21 was not detectable in BEC-CM (o78 pg/ml, n ¼ 6).
The effect of two other chemokines on the melanoma cell migration assay was investigated. Neither CCL20, which acts through CCR6, nor CCL19 caused any significant chemotaxis of the A375 melanoma cells. The by a neutralizing antibody (Ab) to the lymphatic chemokine CCL21 (n ¼ 3) (Po0.0001, one-way ANOVA). (b) A375 melanoma cells migrate towards HDEC-CM and to a greater extent from CM of LECs purified from those HDECs and this was inhibited by a neutralizing antibody to CCL21. In contrast, A375 malignant melanoma cells did not migrate significantly towards CM from BECs purified from those HDECs. n ¼ 3, ***Po0.001, significantly different from HDECs; þ þ þ Po0.001, significantly different from LEC, Bonferroni test. (c) CCL21 itself stimulated melanoma cell migration, which was significantly attenuated by a neutralizing antibody. VEGF-C did not add to the response to CCL21 and VEGFR-3 inhibition did not further inhibit migration and this was unaffected by the VEGFR-3-specific inhibitor MAZ51 or a neutralizing antibody to CCL21. n ¼ 3, *significantly greater than control, þ significantly lower than absence of inhibitor. Bonferroni test, *Po0.05, **Po0.01. respective test/control migration ratios were 1.471.4 and 1.270.68 (n ¼ 6, P>0.1).
Absence of chemotactic response by non-metastasizing melanoma cell line All the above studies assessed the chemotactic migration of human A375 metastatic melanoma cell line. The chemotactic metastasis hypothesis described in the Introduction implies that migration should be specifically of metastatic cancer cells and should not occur with other types of cancer cell. To test this migration, a non-metastatic clone of A375 cells (A375P; Hendrix et al., 1987) was measured in response to HDEC-CM, CCL21 and VEGF-C. As shown in Figure 3a , the migration of the non-metastatic cells towards HDEC-CM (test/control ratio 2.970.7) was much smaller than the migration of metastatic A375 cells, 2474.5 (Po0.001, n ¼ 6). The A375P cells did not migrate significantly in response to CCL21 (1.3670.22-fold) (Figure 3b) . Treatment with the neutralizing antibody to CCL21 did not affect migration of A375P cells. To determine whether other metastatic melanoma cells could respond to LECs, but not BECs, migration of a different metastatic melanoma cell line, A2058 was investigated. A2058 cells migrated 3575-fold more than control to LEC-CM, but 1.270.2-fold more than control to BEC-CM. These results indicate that the chemotactic response to LEC secretions is specific to cancer cells of a metastatic phenotype, in keeping with the chemotactic metastasis hypothesis. LEC-CM did not increase proliferation of A375 cells, as treatment with this CM resulted in a small, insignificant reduction in cell count of 77710% compared with that before treatment, compared with an increase of 223715% for cells treated with 10% fetal calf serum, and no change (96711%) for untreated cells (n ¼ 3). This was confirmed by Ki67 staining (not shown).
Melanoma cells express chemokine receptors in vitro and in vivo
The above results indicate that A375 metastatic melanoma cells should express receptors for the lymphatic chemokine CCL21, namely CCR7 receptors. This was confirmed directly by immunocytochemistry (Figure 4a ). CCR7 was readily detected by immunocytochemistry in metastatic melanoma cells (Figure 4a ). but was difficult to visualize in A375P non-metastatic cells, even by immunohistochemical staining (Figure 4b ). CCR7 expression has previously been shown by Takeuchi et al. (2004) to be expressed in metastatic, but not non-metastatic melanomas. Staining of a small number of tumors (n ¼ 3) confirmed this finding (Figure 4c and d). Western blotting showed clear expression of CCR7 in metastatic A375 and A2058 cells but not non-metastatic A375P cells (Figure 4e ).
Metastatic (but not non-metastatic) melanomas grow towards LECs in vivo A limitation of the above work is that the dynamic studies were conducted in vitro. To test whether lymphatic cells can also induce cancer chemotaxis in vivo, we used a nude mouse model in vivo. To determine whether melanomas grow towards areas of high LEC density in vivo, nude mice were injected subdermally on the midline anterior dorsal surface of the skin with 1 Â 10 6 metastatic melanoma cells (A375, n ¼ 9) or a non-metastatic clone of these melanomas (A375P, n ¼ 9). To ensure that this directed growth was not unique to A375 cells, we repeated the experiment using A2058 (n ¼ 9), a separate metastatic human melanoma cell line. We then injected 1 Â 10 5 endothelial cells (either LEC, on three animals for each tumor or BEC, on the other three animals for each tumor) or 100 ml saline (on three animals for each tumor), 10 mm immediately caudal to each melanoma injection site, also on the midline. The injection sites were identified by a Monastral blue tattoo. All 18 tumors grew to at least 8 mm diameter by day 21, but there was no difference in the size or growth rate of the three tumor types. The tumors and associated skin containing both depot sites were then excised post mortem, photographed and the proportion of the tumor found on the side of the endothelial cell injection site was measured. The area of the A375 and A2058 metastatic melanomas on the side of the LEC injection site was significantly greater than would be predicted by chance (50%), or than is seen in the absence of endothelial cell injection (3278.7%). For the A375 tumors, 8373% of the area of the tumor was on the side towards the LECs (Po0.01 compared with phosphate-buffered saline (PBS), analysis of variance (ANOVA), Student-Newman-Keuls (SNK), n ¼ 3, Figure 5a ), and for the A2058 tumors 7177% of the area of the tumor was on the side towards the LECs (Po0.01 compared with PBS, ANOVA, SNK, n ¼ 6; Figure 5b ). By contrast, the non-metastatic A375P melanoma did not show directed growth towards the LEC injection site (Figure 5c, 16715% , not significantly different to PBS, ANOVA, SNK, n ¼ 3), and their growth on the LEC side of the injection site was significantly lower than that of the malignant A375 or A2058 cells (Po0.01, for both). Neither A375 (Figure 5d ), A2058 nor A375P tumors grew towards BECs. Directed growth values calculated from everted tumor areas (Figure 5e and f for migration to or from LECs for instance) showed that the metastatic tumors migrated towards LEC, but no tumor migrated towards BECs (2877.6% for A375, 4175.1% for A2058 and 4473.6% for A375P; Figure 5g ). The endothelial cells were not visible on day 21, and staining of paraffin sections of the tissue for LECs with LYVE-1 did not allow localization of the cells.
Peri-melanoma lymphatics are negative for an endothelial proliferation marker in human metastatic melanoma To assess active proliferation of LECs at the time point when the melanoma was excised, serial sections of When the tumors reached 8-10 mm as measured through the skin, they were excised, skin laid out and photographed ((e) A375, (f) A375P). The red arrow shows rostral-caudal axis. The areas of tumor caudal and rostral to the melanoma injection site (white arrowhead, M, i.e. below and above the solid white line in (e) were measured and the percent of the tumor caudal to the injection calculated. (g) Percentage of the tumor growing towards the endothelial depot (mean7s.e.m.). Tumors formed by metastatic (A375 and A2058) but not the non-metastatic (A375P) melanoma cells grew and spread disproportionately towards the site where LECs, but not BECs nor saline, were injected caudally. Tumors that grew from all cell types injected without subsequent endothelial cell injection grew on average 32% on the rostral side, owing to the angle of injection (white line in a). Po0.001, ANOVA, **Po0.01 compared with A375P, þ þ Po0.01 compared with PBS (Student-Newman-Keuls).
primary melanomas from 24 patients, 15 metastatic and nine non-metastatic were stained for the cell proliferation marker Ki67 and the lymphatic endothelium marker LYVE-1. The lymphatic profiles were strongly positive for LYVE-1 in the endothelial cells (Figure 6a ). However, these profiles were negative for Ki67 (Figure 6b) . Out of 162 LYVE-1 positive lymphatics, not a single LEC stained positive for Ki67. Ki67 staining was clearly seen in adjacent tumor cells (positive control; Figure 6b ). Some vascular endothelial cells surrounding the tumor stained positive for Ki67, in keeping with the known occurrence of vascular angiogenesis, and providing an additional positive control (Figure 6c ). These results indicate that, at the time of excision, the peri-tumor LECs were not proliferating. Although this does not exclude an earlier period of lymphangiogenesis, it did lead us to make a quantitative comparison between the peri-tumor LD and that in normal dermis.
Lymphatic vessel density in the peri-melanoma zone is within the normal statistical distribution of lymphatic densities in forearm dermis The hypothesis of peri-tumor lymphangiogenesis implies that LD in the peri-melanoma zone should exceed that at a matching site in normal dermis. When comparing LDs, however, the pronounced heterogeneity of lymphatic distribution must be considered as well as mean values (Lubach et al., 1996) . LD is distributed nonuniformly, both with respect to depth (see below) and the surface plane (see Introduction). We quantified LD in normal human dermis with respect to depth, for comparison with peri-melanoma LD. The mean LD across the full thickness of the dermis in normal forearm skin was 4.070.3 vessels per mm 2 cross-section (n ¼ 16 patients), but the mean LD in the superficial 350 mm of the dermis was 10.570.7 vessels per mm 2 , as measured on 80 sections from 16 skin samples. Specifically, the distribution of lymphatic densities has a binomial-like distribution ranging from zero to 28 vessels per mm 2 ( Figure 6d , white bars).
The mean peri-tumor LD within 350 mm of the metastatic melanomas was 11.871.6 vessels per mm 2 (n ¼ 15 tumors) whereas around non-metastatic melanomas it was 5.871.0 vessels per mm 2 (n ¼ 9; see Shields et al., 2004) . Moreover, when the distribution of lymphatic vessel density within 350 mm of the metastatic and non-metastatic melanomas is compared with the distribution of lymphatics in 350 mm of normal forearm dermis (Figure 6d ), a complete overlap was apparent. The metastatic melanoma distribution (black bars) is skewed to the right of those for normal dermis and nonmetastatic melanomas, but the maximum density for the metastatic melanomas is nevertheless within the normal range of the upper dermis, that is, o28 mm À2 . The quantitative LD results thus provided no support for view that lymphangiogenesis is necessary for human malignant melanoma metastasis.
Discussion
The mechanisms that drive metastasis of malignant melanoma cells into the lymphatic system are unknown. The principal new findings were that (a) LECs release a chemokine, CCL21, that stimulates malignant melanoma cell directional migration in vitro; and (b) melanoma in vivo shows directional growth towards an injected depot of LECs. Before considering these novel finding further, we first review briefly the hypothesis that tumor-induced lymphangiogenesis is a major factor in lymphatic metastasis.
Recent studies have shown that tumor cells can produce growth factors that interact with lymphatics, in particular VEGF-C and VEGF-D in breast cancer, prostate cancer, malignant melanoma and others that metastasize via the lymphatics (Akagi et al., 2000; Achen et al., 2001; Skobe et al., 2001; Stacker et al., 2001) . In animal models of xenografted human tumors that over-express VEGF-C and VEGF-D, there is an increased incidence and rate of metastasis to the lymph nodes (Achen et al., 2001; Skobe et al., 2001; Stacker et al., 2001) . In human malignant melanomas, the LD around metastatic melanomas is higher than around non-metastatic melanomas (Dadras et al., 2003; Shields et al., 2004) . This has been assumed to be owing to metastatic-specific lymphangiogenesis. However, in the current study, peri-tumor lymphatic densities, though high, were not outside the normal range for superficial dermis of human forearms. Nor did we find evidence of active lymphangiogenesis at the time of excision even though the efficacy of the proliferation assay was validated by positive controls. This is consistent with other recent studies carried out on breast cancer (Agarwal et al., 2005) and pancreatic carcinoma (Sipos et al., 2005) ; no proliferating LEC, despite higher lymphatic densities and proliferating vascular endothelial cells being visualized. It is of course possible that the lymphangiogenesis preceded removal of the metastasis in every case so far examined and this is the reason for the lack of proliferating LEC.
Given the wide range of lymphatic densities in superficial dermis, the high LD around metastasizing melanomas could be owing to an association with pre-existing lymphatics rather than (or in conjunction with) lymphangiogenesis. This may occur purely stochastically (a tumor that happens to form in a region of locally high LD being more likely to metastasize than one originating in an area of low LD) or by directional growth of the melanoma into a region of dermis that is rich in lymphatic endothelium, that is, chemotaxis. In either case, the LD around the metastatic melanoma would be within the range found in healthy dermis but would be at the higher end of the normal range, as found here.
The chemotactic metastasis hypothesis requires a paracrine mechanism, and the chemotactic chamber studies identified one such paracrine agent. LECs secrete cytokines and the melanoma cells possess receptors for these factors, enabling them to recognize the presence of lymphatics. The CM from LECs themselves appeared to cause much more chemotaxis than a concentration of CCL21 that was higher than that found in the LEC-CM. This was not due to a contribution from VEGF-C, as addition of this did not result in any further migration. It may be owing to a synergistic effect of other chemokines, similar to the known synergy between CCL21 and PGE2 in stimulating migration in dendritic cells (Scandella et al., 2002) . The lack of complete inhibition of HDEC-mediated migration by CCL21 antibodies also suggests complementary molecular regulation of chemotaxis. LECs express a wide variety of molecules that are not expressed by blood vascular endothelial cells (Podgrabinska et al., 2002) . Differential isolation followed by microarray studies have shown that the chemokines CCL21, VEGF-C, fibroblast growth factor homologous factor 2, melanoma growth stimulatory activity, IL7, VEGF and angiopoeitin-2 are all expressed or upregulated by LECs, but not by BECs (Podgrabinska et al., 2002) . CCL21 (6Ckine, SLC) is a chemokine thought to be involved in recruitment of T cells and dendritic cells to lymph nodes and is expressed by the lymphatic vessels of many tissues (Gunn et al., 1998; Saeki et al., 1999) . Recent reports have also shown that human (Takeuchi et al., 2004) and murine (Wiley et al., 2001 ) melanomas express CCR7, the receptor for CCL21 and CCL19 and that in gastric carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer and breast cancer these two factors may be associated with lymph node metastasis (Muller et al., 2001; Mashino et al., 2002; Takanami, 2003; Wang et al., 2004; Yan et al., 2004) . In the present study, we showed that two different malignant melanoma cell lines can detect CCL21 in vitro through expression of its cognate receptor CCR7 on melanoma cells, as a result of which the melanoma cells migrated towards the source of the chemokine. Similarly, the mouse xenograft experiments in vivo showed that the malignant melanoma tumors spread preferentially towards areas rich in LEC. A possible advantage for the metastasizing cell is that upregulation of CCR7 will provide a survival advantage by enabling the cell to escape the confines of the tumor. It is also possible that CCL21 stimulates directed growth by increasing proliferation rate, although we saw no evidence of an effect of LEC-CM on melanoma cell growth. Although we have identified CCL21 as a key stimulator, it is possible that other molecules, such as CCL19, VEGF-A and FGF2, etc may also play a role. Although we did not see an effect of CCL19, this may be owing to the requirement for a higher dose than CCL21 to exert its effect on CCR7.
It is likely that both mechanisms (lymphangiogenesis and chemotactic metastasis) contribute to metastasis, to differing extents in different tumors, tissues and individuals. A role for lymphangiogenesis is not excluded by these studies. Indeed, we found that LEC migration was stimulated by VEGF-C produced by melanoma cells in vitro, but we found no convincing evidence for lymphangiogenesis around human malignant melanomas. More importantly, the results show for the first time that cancer cells can recognize and respond to signals given off by the LEC. This core finding points to a potential mechanism that promotes metastasis of malignant melanoma into the lymphatic system. It remains to be seen whether other types of cancer can also recognize molecules secreted by LEC. Nevertheless, the present results point to a mechanistic, molecular explanation for how certain tumor cells home in on the lymphatics to metastasize.
Materials and methods
Cell culture and separation of lymphatic from vascular endothelial cells See online supplement for details of cells.
Chemotactic stimuli In vitro migration assays were carried out using standard Boyden Chamber assay (see online supplement for details).
Animal tumor models in vivo
To investigate directional growth of tumors we developed an in vivo model (see details in Supplementary information).
Nude mice were injected subcutaneously with 1 Â 10 6 tumor cells with a 30-gauge needle, scored and dipped in sterile 5% Monastral blue. The injection point can subsequently be identified by the tattoo mark. An injection of 10 5 human LECs or BECs was then made B10 mm caudal to the tumor cell site with another tattooing needle. After tumors had grown to 8-10 mm, the animals were killed, the skin laid out and photographed. Direction of growth was determined objectively by comparing the measured en face area of the tumor on the EC-facing side with the total area en face. A line (Figure 5a , black line) was drawn from the EC injection site (Figure 5a , arrowhead) to the tumor injection site (Figure 5a, arrow) . A second line perpendicular to the first was drawn through the tumor cell injection site (Figure 5a , white line). This was the dividing line. The tumor area on the EC side of the dividing line was divided by the total tumor area to calculate percentage growth towards the EC depot. A value of 100% represents growth entirely towards the EC depot, whereas a value of 50% represents equal growth towards and away from the ECs, and 0% would represent growth solely in the opposite direction to the EC depot.
Analysis of human tumors
Serial sections of archived human melanoma were stained with LYVE-1 and Ki67 (see online supplement for details). LD was calculated as described previously (Shields et al., 2004) .
Statistical analysis
Results are presented as a mean7s.e.m. Differences in migration and tumor growth were assessed by one-way ANOVA and Bonferroni test or SNK as appropriate.
